Program
SCTV02
A development code.
Its studies are led by Sinocelltech Group.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Sinocelltech Group | 11 open or running | phase 2since Dec 23, 2024 | Dec 23, 2024 | Jul 30, 2027phase 2 · NCT06754605 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Dec 23, 2024First study: phase 2 study in Respiratory Syncytial VirusFirst studyNCT06754605 · 480 planned · China
Ahead
- Jul 30, 2027Primary completion: phase 2 study in Respiratory Syncytial VirusNCT06754605
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 1 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06754605Respiratory Syncytial Virus · China | 2 | Recruiting | Jul 30, 2027 | 480 |
How it is read
Names in the registry
- “SCTV02”, 1 entry
Codes read as this program: SCTV02.
Conditions, from the studies’ own filings
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.